Neuroblastoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Clarity Pharmaceuticals, Y-mabs therapeutics, Eli Lilly

Neuroblastoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Clarity Pharmaceuticals, Y-mabs therapeutics, Eli Lilly
The Neuroblastoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuroblastoma pipeline products will significantly revolutionize the Neuroblastoma market dynamics.

DelveInsight’s “Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Neuroblastoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


To Know in detail about the Neuroblastoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuroblastoma Market Insights


Neuroblastoma Overview

Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). It is derived from two words i.e. “neuro” means nerves and “blastoma” refers to the tumor affecting the immature or developing cells. It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present.


Some of the key facts of the Neuroblastoma Market Report: 

  • The Neuroblastoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In December 2021, Phase II data of hu14.18K322A was published at ASCO journal, data showed improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemo immunotherapy
  • In September 2021, Y-mAbs Therapeutics presented data from phase II trial of Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma
  • According to a study conducted by Shohet et al., the median time to relapse is around 1.5 years from diagnosis
  • Key Neuroblastoma Companies: Clarity Pharmaceuticals, Y-mabs therapeutics, Eli Lilly, LaboratorioElea Phoenix, K C Pharmaceuticals, Autolus Therapeutics, and others
  • Key Neuroblastoma Therapies: 67Cu-SARTATE, Omburtamab, LY 3295668, Racotumomab, Eflornithine, AUTO6NG, and others
  • The Neuroblastoma epidemiology based on gender analyzed that Neuroblastoma affects males slightly more than females


Get a Free sample for the Neuroblastoma Market Report-


Key benefits of the Neuroblastoma Market report:

  1. Neuroblastoma market report covers a descriptive overview and comprehensive insight of the Neuroblastoma Epidemiology and Neuroblastoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Neuroblastoma market report provides insights on the current and emerging therapies.
  3. Neuroblastoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Neuroblastoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Neuroblastoma market.


Download the report to understand which factors are driving Neuroblastoma epidemiology trends @ Neuroblastoma Epidemiological Insights 


Neuroblastoma Market  

The dynamics of the Neuroblastoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  


Neuroblastoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


Neuroblastoma Epidemiology Segmentation:

The Neuroblastoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Neuroblastoma
  • Prevalent Cases of Neuroblastoma by severity
  • Gender-specific Prevalence of Neuroblastoma
  • Diagnosed Cases of Episodic and Chronic Neuroblastoma


Neuroblastoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuroblastoma market or expected to get launched during the study period. The analysis covers Neuroblastoma market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neuroblastoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Discover more about therapies set to grab major Neuroblastoma market share @ Neuroblastoma market forecast 


Neuroblastoma Therapies and Key Companies

  • 67Cu-SARTATE: Clarity Pharmaceuticals
  • Omburtamab: Y-mabs therapeutics
  • LY 3295668: Eli Lilly
  • Racotumomab: LaboratorioElea Phoenix
  • Eflornithine: K C Pharmaceuticals
  • AUTO6NG: Autolus Therapeutics


Neuroblastoma Market Strengths

  • The neuroblast may be caused due to the immature cell growth or mutation in the gene responsible for controlling cell proliferation. 


Scope of the Neuroblastoma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Neuroblastoma Companies: Clarity Pharmaceuticals, Y-mabs therapeutics, Eli Lilly, LaboratorioElea Phoenix, K C Pharmaceuticals, Autolus Therapeutics, and others
  • Key Neuroblastoma Therapies: 67Cu-SARTATE, Omburtamab, LY 3295668, Racotumomab, Eflornithine, AUTO6NG, and others
  • Neuroblastoma Therapeutic Assessment: Neuroblastoma current marketed and Neuroblastoma emerging therapies
  • Neuroblastoma Market Dynamics: Neuroblastoma market drivers and Neuroblastoma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Neuroblastoma Unmet Needs, KOL’s views, Analyst’s views, Neuroblastoma Market Access and Reimbursement 


Neuroblastoma Market Opportunities

  • Understanding of neuroblastoma biology deepens, our approaches to therapy for this disease continue to evolve


Table of Contents 

1. Neuroblastoma Market Report Introduction

2. Executive Summary for Neuroblastoma

3. SWOT analysis of Neuroblastoma

4. Neuroblastoma Patient Share (%) Overview at a Glance

5. Neuroblastoma Market Overview at a Glance

6. Neuroblastoma Disease Background and Overview

7. Neuroblastoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Neuroblastoma 

9. Neuroblastoma Current Treatment and Medical Practices

10. Neuroblastoma Unmet Needs

11. Neuroblastoma Emerging Therapies

12. Neuroblastoma Market Outlook

13. Country-Wise Neuroblastoma Market Analysis (2019–2032)

14. Neuroblastoma Market Access and Reimbursement of Therapies

15. Neuroblastoma Market Drivers

16. Neuroblastoma Market Barriers

17.  Neuroblastoma Appendix

18. Neuroblastoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


To know more about Neuroblastoma treatment, visit @ Neuroblastoma Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States